

Freedom of Information Request	FOI 22-393	13 th September 2022
--------------------------------	------------	---------------------------------

- Q1. How many patients have been treated (for any condition) in the last 4 months with:**
- **Benralizumab**
 - **Omalizumab**
 - **Reslizumab**
 - **Mepolizumab**

Please find below the quantities dispensed from the Health Board pharmacies for the period May 2022 – August 2022.

Please note the Health Board is only able to supply information by quantity and not by the number of patients treated:

Description	Quantity
BENRALIZUMAB 30 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	52
BENRALIZUMAB 30 mg in 1mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	11
MEPOLIZUMAB (NUCALA) 100 mg in 1mL Pre-Filled Pen 1 Pre-Filled Pen Pack	223
OMALIZUMAB 150 mg Pre-Filled Syringe 1 Pre-Filled Syringe Pack	1190
OMALIZUMAB 75 mg Pre-Filled Syringe 1 Pre-Filled Syringe Pack	105

- Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:**
- **Age 6-11**
 - **Age 12-17**
 - **Age 18 and above**

The Health Board does not record this information centrally. Therefore, in order to comply with your request, the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

- Q3. How many patients have been treated in the last 4 months with Dupilumab for:**
- **Asthma ONLY**
 - **Chronic rhinosinusitis with nasal polyps ONLY**

Please find below the quantities dispensed from the Health Board pharmacies for the period May 2022 – August 2022 for respiratory only.

Please note the Health Board is only able to supply information by quantity and not by the number of patients or conditions treated:

Description	Quantity
DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Pen 2 Pre-Filled Pen Pack	31
DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Syringe 2 Pre-Filled Syringe Pack	1

Q4. How many patients have been treated in the last 4 months with Omalizumab for:

- **Asthma ONLY**
- **Chronic rhinosinusitis with nasal polyps ONLY**
- **Chronic Spontaneous Urticaria ONLY**

Please find below the quantities dispensed from the Health Board pharmacies for the period May 2022 – August 2022 for respiratory only.

Please note the Health Board is only able to supply information by quantity and not by the number of patients or conditions treated:

Description	Quantity
OMALIZUMAB 150 mg Pre-Filled Syringe 1 Pre-Filled Syringe Pack	1095
OMALIZUMAB 75 mg Pre-Filled Syringe 1 Pre-Filled Syringe Pack	91